Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
28 12월 2023 - 11:15PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare
technology company focused on developing and commercializing
innovative technology intended to transform care and improve
patients’ lives, supports the decision announced by five Medicare
Administrative Contractors (“MACs”) to withdraw their final local
coverage determinations (“LCDs”) for Micro-Invasive Glaucoma
Surgery (“MIGS”) that were scheduled to take effect on January 29,
2024.
These five MACs, WPS Government Health
Administrators, Palmetto GBA, Celerian Group Company, National
Government Services, and Noridian Healthcare Solutions, previously
published LCDs on MIGS, which identified certain procedures as
investigational for glaucoma management in patients over the age of
18, including canaloplasty in combination with trabeculotomy ab
interno, which is a procedural description associated with the
Company’s OMNI Surgical System (“OMNI”). All five MACs have now
issued statements that the final LCDs will not go into effect on
January 29, 2024. As a result, there will be no change in January
2024 to the current Medicare coverage for MIGS procedures performed
with the OMNI Surgical System.
“We appreciate that the MACs and the Centers for
Medicare & Medicaid Services (“CMS”) carefully and thoughtfully
considered all stakeholder concerns with the LCDs and the serious
potential risks to patient health and access to effective glaucoma
care,” said Paul Badawi, co-founder and CEO of Sight Sciences. “We
look forward to continued engagement with the MACs and CMS to
ensure glaucoma patients and their physicians maintain appropriate
and fair access to medically reasonable and necessary MIGS
procedures and technology. We would like to thank the many
passionate glaucoma surgeons around the country and the national
and state eye care societies including notably the American Academy
of Ophthalmology, the American Glaucoma Society, the American
Society of Cataract and Refractive Surgery, and the Outpatient
Ophthalmic Surgery Society, who all worked collaboratively and
tirelessly to provide valuable and critical feedback to the MACs,
CMS, and Congressional offices during this rigorous review process.
Additionally, we appreciate the support from the Medical Device
Manufacturers Association (MDMA) and numerous patient advocacy
groups.”
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative solutions to transform care and improve
patients’ lives. Using minimally invasive or non-invasive
approaches to target the underlying causes of the world’s most
prevalent eye diseases, Sight Sciences seeks to create more
effective treatment paradigms that enhance patient care and
supplant conventional, outdated approaches. The Company’s OMNI®
Surgical System is a MIGS technology indicated to reduce
intraocular pressure in adult patients with primary open-angle
glaucoma (“POAG”), the world’s leading cause of irreversible
blindness. The Company’s TearCare® System technology is 510(k)
cleared for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”) when used in conjunction with manual expression
of the meibomian glands, enabling office-based clearance of gland
obstructions by physicians to address the leading cause of dry eye
disease. The Company’s SION® Surgical Instrument is a manually
operated device used in ophthalmic surgical procedures to excise
trabecular meshwork.
For more information,
visit www.sightsciences.com.
OMNI, TearCare, and SION are registered trademarks of Sight
Sciences, Inc.© 2023 Sight Sciences. All rights reserved.
Forward-Looking StatementsThis
press release, together with other statements and information
publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which statements are
subject to considerable risks and uncertainties. The Company
intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with these safe harbor
provisions. Any statements made in this press release that are not
statements of historical fact, including statements about our
beliefs and expectations, are forward-looking statements and should
be evaluated as such. Forward-looking statements herein include,
without limitation, statements concerning no change in January 2024
to the current Medicare coverage for MIGS procedures performed with
the OMNI Surgical System, and the Company's intent to continue to
engage with the MACs to ensure appropriate and fair access to
medically reasonable and necessary MIGS procedures. These
statements often include words such as “anticipate,” “expect,”
“suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,”
“projects,” “should,” “could,” “would,” “may,” “will,” “forecast”
and other similar expressions. We base these forward-looking
statements on our current expectations, plans and assumptions that
we have made in light of our experience in the industry, as well as
our perceptions of historical trends, current conditions, expected
future developments and other factors we believe are appropriate
under the circumstances at such time. Although management believes
these forward-looking statements are based upon reasonable
assumptions at the time they are made, management cannot guarantee
their accuracy or completeness. Forward-looking statements are
subject to and involve risks, uncertainties and assumptions that
may cause the Company’s actual results, performance or achievements
to be materially different from any future results, performance, or
achievements predicted, assumed or implied by such forward-looking
statements. Some of the risks and uncertainties that may cause
actual results to materially differ from those expressed or implied
by these forward-looking statements are discussed under the caption
“Risk Factors” in the Company’s filings with the SEC, as may be
updated from time to time in subsequent filings. These cautionary
statements should not be construed by you to be exhaustive and are
made only as of the date of this press release. Sight Sciences
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by applicable law.
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Media contact: pr@SightSciences.com
Sight Sciences (NASDAQ:SGHT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sight Sciences (NASDAQ:SGHT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024